Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and PD of Tinlarebant in Healthy Elderly Volunteers
NCT05667688Phase 1Completed
- Sponsor
- RBP4
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tinlarebant in age-related macular degeneration (AMD) and Stargardt disease (STGD) (2 cohorts), sponsored by RBP4. Primary endpoints: Pharmacokinetics of tinlarebant in plasma up to 168 hours and Concentrations of retinol-binding protein 4 up to 168 hours. Started Nov 2022; status: completed.
02
Drugs
tinlarebant
03
Conditions
age-related macular degeneration (AMD)Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT05667688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667688.